ArticlePharmaceutics2022

Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office.

Diego Alejandro Dri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.